OncoSynergy, Inc.
San Francisco, United States
High Level Pitch

The vision of OncoSynergy, a UCSF spin-out, is to radically improve outcomes for patients with underserved medical needs. We are focusing on orphan cancers such as ovarian cancer as well as other orphan diseases including Ebola Virus Disease (EVD). Our intent is to develop transformative multi-indication platform drugs that change the standards of care, with the goal of leveraging corporate partnerships and enhanced FDA programs to aggressively expedite development to market.

Our pipeline consists of several platform drugs developed at world-class institutions, including by our founders at the University of California, San Francisco and 2013 Nobel Prize in Chemistry awardee, Martin Karplus, Emeritus Professor at Harvard University.

There are no vacancies at this company at the moment.